Orlistat, the active ingredient associated with Alli, is a lipase inhibitor used alongside a reduced-calorie, lower-fat eating plan for adults managing excess weight. It works inside the digestive tract by limiting the amount of dietary fat absorbed, rather than suppressing appetite or acting on the brain. [1]
The product is supplied as capsules. Orlistat is the active substance associated with Alli. The medicine is intended for adults whose weight and health profile make pharmacological support appropriate alongside changes to food intake and physical activity.
The ATC classification for orlistat is A08AB01. This code places it among centrally acting anti-obesity medicines that reduce fat absorption in the gastrointestinal tract.
Orlistat inhibits gastric and pancreatic lipases. These enzymes normally break dietary triglycerides into smaller molecules that the intestine can absorb. When the enzymes are inhibited, part of the fat passes through the bowel without entering the bloodstream.
The medicine is intended for adults whose weight and health profile make pharmacological support appropriate alongside changes to food intake and physical activity.
Dietary fat is too large for direct absorption. Gastric and pancreatic lipases split it into absorbable fatty acids and monoglycerides. Orlistat binds to these enzymes in the digestive tract and reduces their activity.
The undigested fat remains in the intestinal contents and leaves the body in the stool. The action is mainly local, with minimal systemic absorption compared with medicines that act throughout the body. This explains why Alli can produce bowel-related effects without the stimulant effects associated with some older weight-loss treatments.
The medicine must not be used by people with chronic malabsorption syndrome or cholestasis. Malabsorption syndrome already limits nutrient uptake, while cholestasis involves impaired bile flow; reducing fat absorption in either condition can worsen nutritional problems.
Orlistat should not be combined with medicines whose absorption or blood levels may be altered by orlistat without appropriate clinical supervision. Important combinations include:
This medication is not for you if:
People with kidney disease need specific assessment because rare kidney complications have been reported with orlistat, including oxalate-related kidney injury. Those with a history of gallbladder disease, pancreatitis, eating disorders or significant bowel disease also need careful review.
The most common limitations are gastrointestinal. Treatment can be helpful for suitable adults, but bowel urgency, oily stools and faecal leakage may affect daily routines, work or travel.
Bowel effects are the most recognisable adverse effects of orlistat. They result from unabsorbed fat moving through the intestine.
Possible effects include:
These effects are more likely after meals high in fat. They often become easier to manage when fat is divided across meals and portions of fried or greasy food are reduced.
Some people experience urgency unexpectedly. Planning access to toilets during the first weeks can make work or travel less stressful. A thin pad may be useful for someone who has already experienced leakage, although persistent symptoms require clinical review.
Serious reactions are uncommon but require prompt attention. Severe abdominal pain, yellowing of the skin or eyes, dark urine, persistent vomiting, marked weakness, facial swelling or breathing difficulty needs urgent medical assessment.
Alli is supplied as capsules containing orlistat as the active substance. Orlistat inhibits gastric and pancreatic lipases in the digestive tract, limiting the breakdown and absorption of dietary fat. The product is used by adults whose weight and health profile make pharmacological support appropriate alongside changes to food intake and physical activity.
The correct amount varies between strengths and between users, so there is no single amount that suits everyone. Alli capsules are taken by mouth with meals that contain fat, or shortly afterwards according to the product’s authorised directions.
Use follows these practical principles:
A missed dose does not require a replacement dose several hours later. If the meal has already finished and the usual dosing window has passed, leave that dose and resume with the next appropriate meal.
Weight management treatment should have a defined review point. If weight is not falling after a sustained period of correct use and dietary support, the treatment plan needs clinical reassessment. Long-term use also requires attention to vitamin status, bowel symptoms and other medicines.
Orlistat can reduce absorption of vitamins A, D, E and K. A clinician may recommend a multivitamin taken at a separate time, often in the evening, to reduce the chance that the medicine interferes with absorption. This is a specific consideration for people with restricted diets or existing nutritional deficiencies.
Different weight-management approaches work through different biological pathways. Orlistat acts in the intestine, while appetite-focused treatments act through hormonal or central nervous system pathways.
| Approach | Main mechanism | Main limitation |
|---|---|---|
| Alli with orlistat | Reduces digestion and absorption of part of dietary fat | Gastrointestinal effects, especially after high-fat meals |
| Prescription-strength orlistat | Uses the same lipase-inhibition mechanism at a different authorised strength | Requires individual prescribing and monitoring |
| Appetite-focused pharmacotherapy | Reduces hunger or increases fullness through hormonal or central pathways | May cause nausea or other systemic effects and may have different contraindications |
The closest pharmacological comparison is prescription-strength orlistat because the active substance and core mechanism are the same. The distinction relates to authorised strength, clinical supervision and suitability for the individual.
Orlistat differs from appetite-focused medicines because it does not directly reduce hunger. A person who eats in response to stress, cravings or persistent appetite may need a different clinical strategy. A person whose main challenge is calorie-dense food may find the fat-absorption mechanism more relevant.
Brand names and regulatory pathways can change over time, while the pharmacological distinction remains stable: gastrointestinal lipase inhibition is separate from appetite regulation.
Several avoidable habits reduce the benefit of Alli or make side effects worse:
One subtle mistake is judging the medicine too quickly after one meal. Orlistat does not produce a stimulant sensation, and its action is measured through longer-term changes in absorbed calories and body weight.
Another is using the medicine without a plan for meals. A simple food diary can reveal whether symptoms follow fried food, creamy sauces, processed meat or large portions. That information is more useful than guessing which individual ingredient caused the problem.
In clinical practice, doctors usually explain that orlistat is a tool for reducing calorie absorption from fat, not a general appetite suppressant. The medicine works best when the patient can identify high-fat meals and make repeatable changes rather than following a short, extreme diet.
A prescriber will usually assess body mass index, waist-related health risk, diabetes status, blood pressure, kidney function, bowel conditions and current medicines. The review may also cover eating patterns, because frequent high-fat meals can make treatment uncomfortable enough to undermine adherence.
Doctors often focus on tolerability during the first weeks. A patient who understands the connection between meal fat and bowel symptoms is more likely to adjust food portions instead of abandoning treatment after one difficult episode.
The treatment plan should also include a review of weight change, nutrition and vitamin requirements. NICE guidance places pharmacological weight management within a broader programme that includes dietary support and physical activity.
The suitable time is with a main meal containing fat, rather than a fixed clock time. The EMA’s product information reviewed in 2024 describes meal-linked dosing because orlistat acts on dietary fat inside the gut. Taking it with a fat-free meal does not provide the same purpose and may increase unnecessary medicine use. A late evening meal follows the same principle as breakfast or lunch: the meal’s fat content determines whether the dose is relevant.
Do not take an extra capsule to make up for a missed dose. If the meal has ended and the normal dosing window has passed, omit that dose and continue with the next suitable meal. MHRA safety information reviewed in 2025 supports avoiding unplanned extra dosing because this will not restore the missed effect and may worsen bowel symptoms. The next dose should remain within the authorised daily schedule.
The duration depends on weight response, tolerability, nutritional status and the person’s wider treatment plan. NICE guidance updated in 2025 places anti-obesity medicines within ongoing clinical review rather than automatic indefinite use. Long-term treatment may be considered for suitable adults when benefits continue and monitoring remains appropriate. Persistent gastrointestinal effects, poor weight response, vitamin concerns or new medical conditions are reasons to reassess the plan.
The closest pharmacological alternative is prescription-strength orlistat, which uses the same lipase-inhibition mechanism at a different authorised strength. The EMA’s orlistat assessment in 2013 described the shared action of reducing gastrointestinal fat absorption. Appetite-focused medicines work through different pathways and may affect hunger, fullness or glucose regulation instead. The choice depends on medical history, treatment goals, other medicines and tolerance of bowel effects.
A dose acts during the period when dietary fat is being digested in the intestine, rather than producing a full-day appetite effect. The FDA’s orlistat prescribing information reviewed in 2024 explains that the medicine inhibits gastrointestinal lipases in connection with fat digestion. Its practical effect therefore relates to the meal taken around the dose. It should not be used as a reason to take extra capsules after a later high-fat meal.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first week was awkward because I underestimated how much fat was in takeaway food. Once I changed my meals, the urgency settled and the weight loss felt gradual rather than dramatic.
I found it manageable when eating at home. Restaurant meals were harder, and there were two occasions when I needed a toilet quickly. The medicine made me more disciplined about portions.
I expected my appetite to disappear, but that did not happen. The benefit was more connected to changing what I ate. I stopped after ongoing bloating and discussed other options with my clinician.
The first fortnight involved loose stools after meals with cheese or creamy sauces. I kept a food diary, reduced those foods and found the treatment easier to continue.
The results were modest over the first few months. I liked that it did not make me feel stimulated, although remembering the vitamin timing became part of my evening routine.
